Back to search results

Citicoline for Youth Alcohol Use Disorder

This study is looking at how a supplement called citicoline affects the immune system, brain, and thinking abilities in young people (ages 16-22) who may use alcohol. You would receive either 2000mg of citicoline daily or a placebo (an inactive pill that looks the same) for 4 weeks. Researchers will measure specific immune system markers (IL-1B, IL-6, and TNFα) in your blood after 4 weeks to see if citicoline has an effect. The study is currently unclear about its recruitment status, but they plan to enroll 56 participants. If you are between 16 and 22 years old, you might be able to join.

Study design
This is an interventional study planning to enroll 56 participants. It uses a double-blind approach, meaning neither you nor the study staff will know if you are receiving citicoline or the placebo.
What's involved
You would take an oral capsule daily for 4 weeks. You would also have blood tests to measure immune system markers at the end of the 4-week treatment period.
Compensation
Not stated in the trial record.
Follow-up
Your immune system markers will be measured at 4 weeks of treatment. No further follow-up is specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05870111

Citicoline in Youth Alcohol Use Disorder

Active, Not Recruiting
PHASE2Ages 16–22InterventionalTreatment
Medical University of South Carolina
~56 participants
Updated 2026-06-12 on ClinicalTrials.gov
What's tested:Citicoline (cytidine diphosphate-choline)Placebo oral capsule

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Peripheral Cytokine: IL-1B
Measured over 4 weeks of treatment
+7 more outcomes measured

Conditions

Alcohol Use Disorder

Explore related trials

Alcohol use disorder

Where it's being run

1 sites across 1 states
South Carolina1

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Peripheral Cytokine: IL-1B4 weeks of treatment

    Peripheral cytokine (IL-1B) to measure neuroinflammation.

  • Peripheral Cytokine: IL-64 weeks of treatment

    Peripheral cytokine (IL-6) to measure neuroinflammation.

  • Peripheral Cytokine: TNFα4 weeks of treatment

    Peripheral cytokine (TNFα) to measure neuroinflammation.

  • Brain Metabolite: N-acetyl-aspartate4 weeks of treatment

    Magnetic resonance spectroscopy to quantify neurometabolites (N-acetyl-aspartate) in the anterior cingulate.

  • Brain Metabolite: Choline4 weeks of treatment

    Magnetic resonance spectroscopy to quantify neurometabolites (choline) in the anterior cingulate.

  • Neurocognition: Behavioral impulsivity4 weeks of treatment

    Behavioral impulsivity will be measured via the Behavioral Approach/Avoidance Scales (BIS/BAS).

  • Neurocognition: Cognitive Flexibility and Attention4 weeks of treatment

    Cognitive flexibility and attention will be measured via the NIH Toolbox Dimensional Change Card Sort.

  • Neurocognition: Inhibitory Control and Attention4 weeks of treatment

    Inhibitory control and attention will be measured via the NIH Toolbox Flanker Inhibitory Control and Attention.